YOLFTbeta
Onconetix Inc

Onconetix Inc

ONCO · NASDAQ · Healthcare / Biotechnology

3.21USD+0.18 (+5.94%)

Price History

Full chart

Market Stats

Previous Close3.03
Open3.09
Day Range2.91 – 3.35
52-Week Range0.586 – 209.50
Volume70.29K
Market Cap4.51M
P/E (TTM)0.00
Forward P/E0.00
EPS749.08
Dividend Yield0.00%
Beta2.67
50-Day Avg0.7821
200-Day Avg25.10

About

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Karina M. Fedasz
  • Employees2
  • Headquarters201 East Fifth Street, Cincinnati, OH, United States, 45202, USA
  • Websitehttps://www.onconetix.com

Leadership

  • Ms. Karina M. FedaszInterim Chief Financial Officer · b. 1973
  • Mr. Andrew D. Skibo Ph.D.Global Head of Biologics Operations

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00058.47K2.52M815.37K
Growth (%)-----+4217.31%-67.70%
Cost of Revenue5733.06K4.89K6.75K1.19M1.47M182.46K
Gross Profit-573-3.06K-4.89K-6.75K-1.13M1.06M632.91K
Gross Margin-----1927.93%41.80%77.62%
Operating Expense879.66K1.62M3.41M13.47M34.91M57.54M6.98M
Operating Income-880.23K-1.62M-3.42M-13.48M-36.03M-56.49M-6.34M
Operating Margin-----61634.47%-2237.96%-778.16%
EBITDA-821.34K-1.60M-3.41M-13.41M-36.71M-57.60M-13.27M
EBITDA Margin-----62784.10%-2281.88%-1626.95%
Net Income-821.91K-1.60M-3.42M-13.42M-37.41M-58.69M-14.03M
Net Income Margin-----63986.48%-2325.21%-1720.98%
R&D60.17K524.91K1.33M4.13M1.95M154.36K66.13K
R&D as % of Total Revenue----3334.31%6.12%8.11%
Interest Expense---0671.63K1.41M751.00K
Interest Expense % of Total Revenue----1148.76%55.77%92.11%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.08M4.81M3.08M26.31M87.52M28.18M24.93M
Total Liabilities82.62K78.31K1.64M3.92M86.11M18.57M9.16M
Total Equity6.00M4.73M1.45M22.39M-5.60M9.61M15.76M
Cash6.05M4.31M1.93M25.75M4.55M646.50K5.22M
Total Debt----9.89M9.45M48.77K
Net Debt-6.05M-4.31M-1.93M-25.75M5.33M8.80M-5.17M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-825.13K-1.73M-2.04M-8.68M-13.58M-10.50M-9.68M
Investing Cash Flow-4.50K-11.79K-1.92K-32.66K-8.65M-28.47K-
Financing Cash Flow6.88M0-334.19K32.53M1.04M6.74M14.45M
Capital Expenditure4.50K11.79K1.92K9.34K55.04K28.47K0
Free Cash Flow-829.63K-1.74M-2.05M-8.68M-13.64M-10.52M-9.68M
Dividends Paid-----206.40K409.51K
FCF to OCF100.55%100.68%100.09%100.11%100.41%100.27%100.00%
Dividend Paid to FCF------1.96%-4.23%

Earnings

Report DateNov 5, 2021Feb 23, 2022May 13, 2022Aug 15, 2022Nov 10, 2022Mar 9, 2023May 12, 2023Aug 14, 2023Nov 17, 2023Mar 7, 2024May 20, 2024Aug 12, 2024Nov 7, 2024Mar 6, 2025May 30, 2025Aug 29, 2025Nov 28, 2025Mar 12, 2026May 11, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate0.000.00---0.27-0.20-34850.02-0.18-32300.02-0.21-0.21----0.000.000.000.00--
EPS Actual-0.05-0.12-0.34-0.36-918.00-680.00-30600.02-612.00-52700.03-3404.00-0.50-2191.49-249.08-2.93-45.44-4.18-6.250.000.00-1.28-
Surprise-----339900.00%-339900.00%12.20%-339900.00%-63.16%-1620854.67%-139.05%----------
Timing------After-hours-After-hours-After-hours----------

Key Statistics & Ratios

Market Cap4.51M
Enterprise Value-2.76M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.99
Price / Book0.22
EPS749.08
Book Value3.55
Revenue (TTM)645.82K
Gross Profit (TTM)519.23K
EBITDA-7.67M
Profit Margin0.00%
Operating Margin-13112.09%
Return on Equity-105.23%
Return on Assets-27.03%
Shares Outstanding4.38M
Shares Float3.95M
Beta2.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 9.00
  • Hold
    1

Ownership Breakdown

Institutions
6.61%
Insiders
0.15%
Retail / Other
93.24%

Top Institutional Holders

  • Geode Capital Management, LLC
    11.85K0.10%
  • Citigroup Inc
    1.72K0.01%
  • UBS Group AG
    1.58K0.01%
  • Tower Research Capital LLC
    1.45K0.01%
  • SBI Securities Co Ltd
    1200.00%
  • DRW Securities, LLC
    00.00%
  • Danske Bank A/S.
    00.00%
  • XTX Topco Ltd
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    7.08K0.16%

Stock Splits

  • Nov 6, 20261:10
  • May 21, 20261:10
  • Mar 25, 20261:5
  • Jun 13, 20251:85
  • Sep 24, 20241:40